Prelude Therapeutics (PRLD) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Insider Purchase: Chief Chemistry Officer of $PRLD (PRLD) Buys 3,075 Shares
Quiver QuantitativeDec 26 08:15 ET
Insider Spends US$99k Buying More Shares In Prelude Therapeutics
Simply Wall StDec 22 07:00 ET
Morgan Stanley Maintains Prelude Therapeutics(PRLD.US) With Sell Rating
Moomoo NewsDec 12 05:31 ET · Ratings
Prelude Therapeutics (PRLD) Gets a Sell From Morgan Stanley
TipRanksDec 12 05:28 ET · Ratings
Prelude Therapeutics Analyst Ratings
BenzingaDec 11 12:22 ET · Ratings
Prelude Therapeutics Reports Promising Interim Data for PRT2527 in Relapsed/Refractory Lymphoid Malignancies, Plans Partnership for Future Development
Quiver QuantitativeDec 11 07:40 ET

Comments

Teo knows

Dec 20 11:18

$Prelude Therapeutics (PRLD.US)$ iam out ty

Trytosaveabit

Dec 11 06:39

Update

$Prelude Therapeutics (PRLD.US)$ Reuters· 5 mins ago
Prelude Therapeutics Inc: Plans to Seek a Partner for Future Development of PRT2527 in Hematologic Malignancies

1

Jaguar8

Dec 11 06:31

NEWS

$Prelude Therapeutics (PRLD.US)$
Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies
Wednesday, 11th December at 7:30 am
• PRT2527 demonstrated activity across a range of relapsed/refractory lymphoid malignancies, including patients who received prior CAR-T therapy
• Prelude plans to seek a partner for future development of PRT2527 in hematol...

Jaguar8

Sep 13 10:47

NEWS

$Prelude Therapeutics (PRLD.US)$
Prelude Therapeutics’ SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial
Prelude Therapeutics (NASDAQ: PRLD) announced promising initial clinical data for PRT3789, its first-in-class SMARCA2 degrader, in a Phase 1 trial. The drug showed encouraging anti-tumor activityin patients with SMARCA4-mutated non-small cell lung cancer (NSCLC) and esophageal cancer. Key findings include:
- 3 confirmed partial re...

Stock Region

Jul 10 10:17

Therapeutics Company Announces Major Clinical Collaboration With Merck

Prelude Therapeutics and Merck Announce Clinical Collaboration to Evaluate PRT3789 with KEYTRUDA® in SMARCA4-Mutated Cancers.
On July 10, 2024, Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, announced a clinical collaboration with Merck. This collaboration aims to evaluate the efficacy of Prelude's investigational drug, PRT3789, in combination with Merck's established anti-PD-1 t...

PRLD Prelude Therapeutics

Trade Overview

Capital Trend

News

Comments